Is lack of surgery for older breast cancer patients in the UK explained by patient choice or poor health? A prospective cohort study

K Lavelle[*,1,2], A M Sowerbutts[1,2], N Bundred[2,3], M Pilling[1,2], L Degner[1,2], C Stockton[2,3] and C Todd[1,2]

[1]School of Nursing, Midwifery & Social Work, Jean McFarlane Building, University Place, The University of Manchester, Oxford Road, Manchester M13 9PL, UK; [2]Manchester Academic Health Sciences Centre (MAHSC), Core Technology Facility, 46 Grafton Street, Manchester M13 9NT, UK and [3]Nightingale and Genesis Prevention Centre, University Hospital of South Manchester NHS Foundation Trust, Wythenshawe Hospital, Southmoor Road, Manchester M23 9LT, UK

Background: Older women have lower breast cancer surgery rates than younger women. UK policy states that differences in cancer treatment by age can only be justified by patient choice or poor health.

Methods: We investigate whether lack of surgery for older patients is explained by patient choice/poor health in a prospective cohort study of 800 women aged ⩾70 years diagnosed with operable (stage 1–3a) breast cancer at 22 English breast cancer units in 2010–2013. Data collection: interviews and case note review. Outcome measure: surgery for operable (stage 1–3a) breast cancer <90 days of diagnosis. Logistic regression adjusts for age, health measures, tumour characteristics, socio-demographics and patient's/surgeon's perceived responsibility for treatment decisions.

Results: In the univariable analyses, increasing age predicts not undergoing surgery from the age of 75 years, compared with 70–74-year-olds. Adjusting for health measures and choice, only women aged ⩾85 years have reduced odds of surgery (OR 0.18, 95% CI: 0.07–0.44). Each point increase in Activities of Daily Living score (worsening functional status) reduced the odds of surgery by over a fifth (OR 0.23, 95% CI: 0.15–0.35). Patient's role in the treatment decisions made no difference to whether they received surgery or not; those who were active/collaborative were as likely to get surgery as those who were passive, that is, left the decision up to the surgeon.

Conclusion: Lower surgery rates, among older women with breast cancer, are unlikely to be due to patients actively opting out of having this treatment. However, poorer health explains the difference in surgery between 75–84-year-olds and younger women. Lack of surgery for women aged ⩾85 years persists even when health and patient choice are adjusted for.

Older women experience higher incidence and worse survival for breast cancer compared with younger women. Incidence doubles from 202 out of 100 000 for women aged 45–49 to 409 out of 100 000 for those aged ⩾85 years (England 2009) (ONS, Office of National Statistics, 2011). Relative five year breast cancer survival decreases with age from 89% for 40–49-year-olds to 69% for women aged ⩾80 years, a drop not seen in the United States and Western European countries (Coleman *et al*, 2011; Cancer Research UK, 2012). The King's Fund indicates that improved management of older cancer patients could increase cancer survival in England (Foot and Harrison, 2011), and it has been estimated that more than 14 000 cancer deaths could be avoided each year in

the UK for people aged ⩾75 years if our mortality rates matched those of the USA (Moller *et al*, 2011).

Previous studies demonstrate significant and substantial differences in the management of older women with breast cancer compared with younger women (Bouchardy *et al*, 2007; Louwman *et al*, 2007). Older women are less likely to be managed in line with the treatment guidelines. Specifically, they are less likely to undergo primary surgery and are also less likely to have follow-up adjuvant treatments such as radiotherapy and chemotherapy (Wyld *et al*, 2004; Giordano *et al*, 2005; Naeim *et al*, 2006; Lavelle *et al*, 2007b). Around 60% of women aged ⩾80 years in England do not have surgery for breast cancer compared with <10% of younger age groups (Lavelle *et al*, 2007a,b, 2012; Lawrence *et al*, 2011).

There are many reasons why treatment could vary with age, but UK national cancer strategy has identified 'patient choice' and 'poor health' as the only 'acceptable' reasons for older breast cancer patients not receiving clinically appropriate treatment (DH, Department of Health, 2007, 2011). A systematic review comparing surgery plus endocrine therapy with endocrine alone in women aged ⩾70 years concludes that surgery should only be omitted in women who are 'unfit for, or refuse, surgery' (Hind *et al*, 2007, p 1029). A recent UK Parliamentary Inquiry into older age and breast cancer states that 'the pressing question is whether the reduced level of treatment observed in older breast cancer patients is justified' and highlights that adjusting for patients' co-morbidities and frailty would help establish whether older people with breast cancer are being 'inappropriately undertreated' (APPGBC, All Party Parliamentary Group on Breast Cancer, 2013, p 17).

Our previous studies suggest that older women in the UK are receiving non-standard treatment for breast cancer for reasons other than having poorer general health (Lavelle *et al*, 2007b, 2012), as defined by co-morbidity and increasing dependence in Activities of Daily Living (ADL) (functional status). Patients aged ⩾80 years, attending breast cancer units in Greater Manchester between 2002–2003, had 44 times the odds of not receiving surgery for operable breast cancer compared with patients aged 65–79 years, controlling for co-morbidity and functional status (Lavelle *et al*, 2007a). Several national policies, guidelines (DH, Department of Health, 2000, 2007, 2011) and initiatives (MacMillan Cancer Support, Age UK and the Department of Health, 2012) have specifically addressed the issue of access to treatment for older cancer patients. This may well have increased surgical rates among older cancer patients over the last decade. Using routine registration data we recently investigated over 23 000 women aged ⩾65 years, registered with breast cancer in Northern Yorkshire and West Midlands, and showed surgery rates rose from 67.4% in 1997–1999 to 75.1% in 2003–2005 (Lavelle *et al*, 2012). After adjustment for co-morbidity, older age still predicted lack of surgery. Compared with 65–69-year-olds, the odds of surgery decreased from 0.74 (95% CI: 0.66–0.83) for 70–74-year-olds to 0.13 (95% CI: 0.11–0.14) for women aged ⩾85 years. However, co-morbidity is likely to be underestimated as the routine data sources are limited to inpatient stays only. Moreover, no data on wider measures of health such as patient frailty or functional status are routinely collected in the UK, so could not be included. Functional status has been shown to vary independently from co-morbidity (Extermann *et al*, 1998) and has been found to account for some of the difference in surgical treatment between younger and older breast cancer patients (Lavelle *et al*, 2007a).

One explanation for differences in the treatment is that older women may choose non-standard treatment (e.g., decline surgery). No measure of patient choice was adjusted for in these previous UK studies. Tang *et al* (2011) found that of women aged ⩾70 years, diagnosed with early stage breast cancer in Nottingham (England), who were offered a choice between surgery or treatment with hormone therapy, 58.9% did not have surgery. However,

no adjustment was made for age and health in multivariable analysis. The residual variation in access to surgery, not explained by choice and health, could therefore not be estimated. Taking account of patient preference in multivariate models has been attempted in two US studies (Silliman *et al*, 1997; Mandelblatt *et al*, 2000). Both adjusted for physical health status as measured by the Short Form-36 (Ware *et al*, 2002) and whether treatment options had been offered/discussed. However, older age remained the strongest predictor of not receiving standard treatment, after adjusting for these measures of patient health and choice. The generalisability of these results to the UK is limited by differences between the health care systems and survival rates (Coleman *et al*, 2008). Moreover, even when a treatment choice is offered, the patient could defer to the doctor's advice. There is evidence that older women with breast cancer prefer (and are more likely) to do this (Degner *et al*, 1997), suggesting that non-standard management of older women is more likely to be the result of the doctor's rather than the patient's decision. This needs to be tested in a study in which perceptions of responsibility for the treatment decision for non-standard management are also measured and adjusted for.

The current study therefore investigates the extent to which the lack of surgery for older patients is justified by patient choice or poor health and, thereby, whether (and if so the extent to which) 'inappropriate undertreatment' (as defined by national policy) occurs among older breast cancer patients in the UK.

MATERIALS AND METHODS

Study design. This is a prospective, cohort study of a consecutive series of women diagnosed with operable (stage 1–3a) breast cancer attending 22 breast cancer units predominantly in North-west England, over a period of 33 months. Data on patient preferences, tumour characteristics, general health and treatment were collected by patient interviews and case note review. The primary outcome measure is primary surgery for operable (stage 1–3a) breast cancer within 3 months of diagnosis. Explanatory variables adjusted for include age, measures of health, patient choice, tumour characteristics, demographics and hospital resources.

Measures of health. Reflecting WHO's definition of health as 'a state of complete physical, mental and social well-being and not merely the absence of disease and infirmity' (WHO, 1948), a range of health measures, representing patient's functional/health status and Health Related Quality of Life (HRQoL) in addition to co-morbidity and other clinical measures, were considered. Measures have primarily been selected based on ease of administration, validity, reliability, acceptability to older people (Sturgis *et al*, 2001; Haywood *et al*, 2004), and prediction of non-standard management (Lavelle *et al*, 2007a) and/or treatment outcomes (Audisio *et al*, 2005). Measures include: Elderly Population Health Status Survey's (ELPHS) ADL (Sharples *et al*, 2000) functional status measure, Short Form-12 (SF-12) (Ware *et al*, 2002) health status measure, European Organisation for Research and Treatment of Cancer EORTC-C30 measure of HRQoL (Osoba *et al*, 1997), Eastern Co-operative Oncology Group-Performance Status (Oken *et al*, 1982), 6 item Cognitive Impairment Test (6CIT) (Brooke and Bullock, 1999), smoking status, body mass index (Bertin *et al*, 1998; Sorensen *et al*, 2002) and Charlson Index of Co-morbidity (Charlson *et al*, 1987).

Patient choice. The Control Preferences Scale (CPS) has a component Perception Scale (Degner *et al*, 1997; Janz *et al*, 2004), which we used to examine the extent to which older patients were given and made the choice of whether or not to have surgery from the perspective of both the patients and their surgeons. The CPS Perception Scale measures perceptions of responsibility for the treatment decision (see Table 1), presenting the patient/surgeon

Option	Physician perception scale[b]	Patient perception scale[c]
A	The patient made the final decision about which treatment she would receive.	I made the final decision about which treatment I would receive.
B	The patient made the final decision about which treatment she would receive after seriously considering my opinion.	I made the final decision about[d] my treatment after seriously considering my doctor's opinion.
C	I shared responsibility with the patient for making the final decision about the treatment she would receive.	My doctor and I shared responsibility for deciding which treatment was best for me.
D	I made the final decision about which treatment the patient would receive after seriously considering the patient's opinion.	My doctor made the final decision about which treatment would be used but seriously considered my opinion.
E	I made the final decision about which treatment the patient would receive.	My doctor made the final decision about which treatment I would receive[e].

Table 1. Control preferences scale[a]

[a]Degner *et al* (1997).
[b]Janz *et al* (2004).
[c]Modified from Janz *et al* (2004).
[d]'Selection of' changed to 'decision about' to correspond more closely with other responses and scales.
[e]'All the decisions regarding my treatment' changed to ' the final decision about which treatment I would receive' to correspond more closely with Physicians Perception Scale and to avoid patient confusion, that is, referring to the treatment decision for surgery vs no surgery not the treatment decision for type of surgery.

with five corresponding response alternatives along a continuum, from the patient to the doctor solely making the treatment decision. The Patient Perception Scale is used to elicit patients' perceptions of who made the decision of whether or not to have surgery. In a subgroup, we also use the Physician Perception Scale to investigate surgeons' perceptions of the same decision for the same consultations (Janz *et al*, 2004). The patient can then be classified as passive (i.e., surgeon made decision) *vs* collaborative/active (i.e., patient shared in or made decision). The scale can only be applied to consultations where a treatment option has been considered. An additional category of 'not discussed' is therefore also included.

Tumour characteristics. Pre-treatment assessments of tumour characteristics, tumour size, stage, nodal and steroid receptor status were recorded based on clinical, imaging and fine needle/core biopsy assessments (cTNM (UICC, 2009)).

Socio-demographics. Socio-economic class is measured using the National Statistics Socio-Economic Classification (ONS, Office of National Statistics, 2013) and based on the main occupation pre-retirement if retired and the highest classification if the participant was married or living with a partner. Ethnicity was recorded based on the census classification categories (ONS, Office of National Statistics, 2010).

Study population. Of the 22 breast cancer units in the study 19 are based in the North West of England, 2 in London and 1 in the Midlands. Surgeons' views of the surgical treatment decisions were also collected after each relevant consultation in a subgroup of 12 breast cancer units only, mainly based in Greater Manchester. The restriction of this subset was largely due to the feasibility of obtaining surgeons' views within a manageable geographical area.

Inclusion criteria

Women. Men were not included as <1% of all invasive breast cancer occurs in men (ONS, Office of National Statistics, 2011) and surgical management differs (SIGN, Scottish Intercollegiate Guidelines Network, 2005; ABS at BASO, Association of Breast Surgeons at British Association of Surgical Oncologists, 2009; NICE, National Institute for Clinical Excellence, 2009).

Aged $\geqslant$ 70 years. Previous studies suggest that odds of not receiving surgery significantly increase from age 70 (Lavelle *et al*, 2012). Women aged 70–74 years are included as a reference group.

Diagnosed with a new episode of operable invasive breast cancer (stage 1–3a). Carcinoma *in situ*, stage 3b, metastatic and recurrent breast cancers are not included as the standards for operable breast cancer do not apply (SIGN, Scottish Intercollegiate Guidelines Network, 2005; ABS at BASO, Association of Breast Surgeons at British Association of Surgical Oncologists, 2009; NICE, National Institute for Clinical Excellence, 2009).

Screening and accrual. The study was phased in at 16 sites from July 2010 to October 2010 and 6 sites joined the study later. Recruitment ended in sites from October 2012 to April 2013. At 10 sites we recruited patients from age 65 years to take part in a further study of diagnostic tests and follow-up treatments. Apart from the lower age limit, the studies are identical and we include patients aged $\geqslant$ 70 in this paper. During the recruitment period 2631 patients were screened for eligibility, 1923 approached by the Trust staff to take part in the study and 1004 recruited (52%). Following initial recruitment, 200 patients were excluded (Figure 1). For a further four patients we were unable to obtain case notes for review, leaving 800 included patients aged $\geqslant$ 70 years.

Data collection. Eligible patients were identified at diagnosis by Multi-Disciplinary Team meetings, clinic lists and hospital computer systems by research nurses. A patient information pack was given to patients in clinic and followed up by telephone call. Patients who agreed to take part were interviewed within 30 days of diagnosis and (if they were having surgery) before surgery took place. The interview comprised demographic variables and measures of health as detailed above. CPS cards elicited patients' perceived role in the surgical decision. In 12 of the 22 sites surgeons' perceptions (CPS) were also recorded. In these sites following a consultation, in which the decision for surgery or not was taken for each eligible patient, the surgeon completed the CPS scale (Table 1). The case notes of each patient were reviewed at 3 months post-diagnosis, or later, using a proforma developed to collect data on tumour characteristics at diagnosis, treatments undertaken and co-morbidity. Inter-rater agreement levels for the proforma all satisfied kappa >0.6 indicating substantial to perfect agreement (Landis and Koch, 1977). Three per cent of case note review proformas and 8% of patient interviews were tested for data input errors. Error rates per data item inputted were <0.5% so no further data-checking was required.

Sample size. In order to test whether patients' health and role in the surgical treatment decision predicts surgery among women

Figure 1. Recruitment and retention of patients in the study.

aged $\geqslant 70$ with operable breast cancer, the recommended sample size is determined by the number of explanatory variables included in the logistic regression model predicting surgery in order to avoid over-specification. For reliable modelling, logistic regression should have at least 10 cases for each explanatory variable for both categories of a binary dependant variable (Peduzzi et al, 1996; Bland, 2005). The main limiting factor is therefore the number of patients not receiving primary surgery for operable breast cancer (17% in our previous study (Lavelle et al, 2007a) – a 1 : 4.9 ratio of no surgery to surgery). To have at least 10 times as many cases as variables for patients not receiving surgery, we therefore need 110 patients not receiving surgery to allow a maximum of 11 explanatory variables. This requires 539 patients receiving surgery and thus the rule-of-thumb recommends having at least 649 patients in the final model.

Analyses. Explanatory variables were investigated in univariable analysis using Pearson's χ^2 test, Fisher's exact test, χ^2 test for trend and univariable logistic regression analyses to generate odds ratios (two tailed with $\alpha = 0.05$). The distribution of continuous variables was assessed for normality using the Shapiro–Wilk W-test. Associations between non-normal variables and surgery/age group were investigated using the non-parametric two-sample Wilcoxon rank sum (Mann–Whitney test) and Kruskal–Wallis equality-of-populations rank test, respectively. Associations for parametric variables were investigated using the two-sample t-test.

Indicators of standard management found to be significantly associated with surgery in univariable analyses were used as independent variables in the subsequent logistic regression (forward stepwise). The model was built in line with our Data Analyses Plan agreed a priori with the project's Independent Data Monitoring Committee modifying an approach suggested by Hosmer and Lemeshow (2000). A base model containing explanatory

variables of primary clinical importance to the study was constructed including age group, patient role in surgical decision and co-morbidity (as the only measure of pre-existing disease). The remaining explanatory variables were considered unless the significant effect was only in the 'missing' category of data. Variables were considered in three groups and added into the model in order of importance to the primary aim of the study, that is, health measures, tumour characteristics and then socio-demographics. Within each group the order in which variables were added into the model was determined by Bayesian Information Criterion (BIC) values of each variable added into the model individually. Variables with lower BIC values were added in sequentially starting with the variable giving the lowest value. At each step an individual variable's contribution to the model was assessed using two criteria: (1) the difference between the model with the additional variable and the previous model using the Likelihood Ratio Test (a.k.a. analysis of deviance) and (2) producing a significant coefficient in the model (both at a 5% significance level). In order to reduce the likelihood of multi-collinearity and to ensure the number of cases in the model could sustain the potentially high number of health measures, they were only retained in the model if they produced both a significant coefficient and likelihood ratio test. Tumour characteristics and socio-demographic variables were retained if they had a significant likelihood ratio test only. Once each group of variables had been added variance inflation factors were checked and variables exhibiting factors above 10 removed to prevent multicollinearity (Kutner et al, 2004).

In order to retain sufficient number of cases to support the subgroup analysis, which includes surgeons' perceptions in a nested model, all variables with non-significant coefficients were removed from the final main model. In addition one health measure was selected and retained as representative of the remaining health measures. Both the main and nested models were tested for goodness of fit (Hosmer & Lemeshow) and discrimination (area under receiver operating characteristic curve). Data were analysed using STATA version 12.

RESULTS

Sample characteristics. Eight hundred women were included, of whom 83.0% (664) had surgery (95% CI: 80.4–85.6%) and 48.0% had a Charleson co-morbidity score of $\geqslant 1$ (95% CI: 44.5–51.5%). Ages ranged from 34% aged 70–74 years, 30% 75–80 years, 19% 80–84 years to 17% aged $\geqslant 85$ years (Table 2). The sample was predominantly of professional/intermediate social class and white ethnic group. Over half were treated at a district general hospital rather than a university teaching hospital. The majority of participants (62.4%) believed that the option of having surgery (vs not having surgery) was not discussed with them. Of the 35.2% who felt it was discussed, nearly twice as many identified themselves as active/collaborative vs passive in making this decision. Conversely, 62.2% of surgeons indicated that the option of no surgery vs surgery was discussed with the patient. More than double the proportion of surgeons identified patients as active/collaborative in this decision (52.8%) than patients did themselves (22.9%). Of the 480 patients for whom the surgeon CPS was not missing, 473 had a corresponding patient CPS referring to the same index consultation (Table 3). Of these, in 249 cases the patient and the surgeon selected the same option regarding the patient's role in the surgical decision (52.6%) giving a kappa value of 0.261, indicating fair agreement (Landis and Koch, 1977). The majority of disagreement is due to the 123 cases (26.0%) in which the patient felt the option of surgery vs no surgery was not discussed but the surgeon felt that it was and that the patient was active/collaborative in this discussion.

Table 2. Socio-demographics, and role in surgical decision, by surgery

Variable	Category	n	Percent	No. surgery	Per cent surgery	P*
Age group (years)	70–74	275	34.4	257	93.5	
	75–79	236	29.5	201	85.2	
	80–84	151	18.9	127	84.1	
	85 +	138	17.3	79	57.3	<0.001[a]
Socio-economic classification	Professional	421	52.6	358	85.0	
	Intermediate	198	24.8	169	85.4	
	Manual	171	21.4	131	76.6	**0.030[b]**
	Missing	10	1.3	6	60.0	**0.015[c]**
Ethnicity	White	769	96.1	643	83.6	
	Other	18	2.3	14	77.8	0.519[c]
	Missing	13	1.6	7	53.9	**0.020[c]**
Hospital type	Teaching/Uni	330	41.3	287	87.0	
	District	470	58.8	377	80.2	**0.012[b]**
Patient's view of their role in decision: surgery vs no surgery CPS	Active/collab	183	22.9	124	67.8	
	Passive	98	12.3	64	65.3	
	Not discussed	499	62.4	460	92.2	**<0.001[b]**
	Missing	20	2.5	16	80.0	**<0.001[c]**
Surgeon's view of patient's role in decision: surgery vs no surgery CPS (base for % n = 553)[d]	Active/collab	292	52.8	224	76.7	
	Passive	52	9.4	41	78.9	
	Not discussed	136	24.6	129	94.9	**<0.001[b]**
	Missing	73	13.2	59	80.8	**<0.001[c]**
	Not included[d]	247	na	na	na	
Total		**800**	**100%**			

Abbreviation: CPS = Control Preferences Scale. *P-values for each variable for complete data reported first followed by data including missings if relevant.
P-values <0.05 are shown in bold.
[a] χ^2 squared test for trend.
[b] χ^2 squared Pearson.
[c] Fisher's exact test.
[d] Surgeons' views only taken in the nested study.

Table 3. Patients' vs surgeons' views of patient's role in decision to have surgery or not

	Surgeon's view of patient's role in surgical decision			
Patient's view of their role in surgical decision	Active/collaborative	Passive	Not discussed	Total
Active/collaborative	**126**	8	9	143
Passive	37	**11**	15	63
Not discussed	123	32	**112**	267
Total	286	51	136	473

Agreement = 52.6%, Kappa = 0.261, P<0.001. Agreed values shown in bold italics.

Just over 40% of the sample were recorded with stage I disease at diagnosis; 58.3% were stage II or IIIa and were hence regarded as having early operable breast cancer (SIGN, Scottish Intercollegiate Guidelines Network, 1998) (Table 4). Over two thirds of the sample (70.1%) had no nodal involvement recorded at diagnosis and over half the sample had small tumours of ⩽20 mm (53.9%). The vast majority of participants were steroid receptor positive for either oestrogen or progesterone receptors (85.5%).

Univariable analysis. Only 57.3% of patients aged ⩾85 years underwent surgery for their operable breast cancer compared with 93.5% of women aged 70–74 years (P<0.001) (Table 2). The proportion undergoing surgery was over 8% less among manual socio-economic classes compared with professional/intermediate

participants (P = 0.030). Surgical rates ranged across the 22 sites from 67.7–96.4%, but this difference was not statistically significant (Fisher–Freeman–Halton Exact, P = 0.139). There was a slight but significantly greater surgical rate in university/teaching hospitals (87.0%) compared with district general hospitals (80.2%) (P = 0.012).

Participants were less likely to get surgery if they presented with later stage (P = 0.003) larger (P = 0.003) breast tumours (Table 4). Mean difference in tumour size was 2.99 mm between patients having surgery (21.28 mm) vs not having surgery (24.27 mm) (two-sample t-test with equal variance P = 0.011). Participants were more likely to have surgery if they were negative for oestrogen and/or progesterone steroid receptors.

All of the self reported measures of health demonstrate significantly worsening health with increasing age (Table 5). Participants aged ⩾85

Table 4. Tumour characteristics at diagnosis by surgery

Variable	Category	n	Percent	No. surgery	Percent surgery	P*
Stage	I	334	41.8	293	87.7	
	II and IIIa[a]	466	58.3	371	79.6	**0.003[c]**
Nodes involved	Yes	239	29.9	197	82.4	
	No/NR	561	70.1	467	83.2	0.778[c]
Tumour size	≤20 mm	431	53.9	374	86.8	
	>20≤50 mm	329	41.1	260	79.0	
	>50 mm	22	2.8	15	68.2	**0.003[d]**
	Missing	18	2.3	15	83.3	**0.007[d]**
Grade	1	138	17.3	112	81.2	
	2	428	53.5	348	81.3	
	3	168	21.0	145	86.3	0.213[b]
	Missing	66	8.3	59	89.4	0.220[c]
Oestrogen receptor ER status	Positive	667	84.6	549	81.1	
	Negative	85	10.6	79	92.9	**0.006[d]**
	Missing	38	4.8	36	94.7	**0.002[d]**
Progesterone receptor PR status	Positive	523	65.4	417	79.7	
	Negative	188	23.5	166	88.3	**0.008[d]**
	Missing	89	11.1	81	91.0	**0.002[d]**
ER or PR positive	Yes	684	85.5	555	81.1	
	No	72	9.0	68	94.4	**0.003[d]**
	Missing	44	5.5	41	93.2	**0.002[d]**
Total		800	100%			

Abbreviations: ER = oestrogen receptor; PR = progesterone receptor; NR = not reported. P-values <0.05 are shown in bold. *P-values for each variable for complete data reported first followed by data including missings if relevant.
[a]Includes 17 patients with stage IIIa.
[b]χ^2 squared test for trend.
[c]χ^2 squared Pearson.
[d]Fisher's exact test.

years were more likely to have difficulty or need help with ADL ($P<0.001$) with over 50% of this age group, also having a ECOG performance status of 2 or more, compared with 21–37% of younger women ($P<0.001$). The proportion experiencing mild to moderate cognitive problems according to the 6CIT screening tool was over twice as large among women aged ≥85 years (30.1%) compared with younger age groups (≤14%) ($P<0.001$). Body mass index reduced with age ($P<0.001$) and a greater proportion of those aged over 80 years were non-smokers compared with younger women ($P=0.008$). There was over a 10% increase in the proportion scoring 1 or more on the Charlson co-morbidity index: from 41.1% of 70–74-year-olds to 52.9% of ≥85-year-olds ($P=0.016$).

All measures of health were significantly associated with receipt of surgery (Table 5), with poorer health decreasing the likelihood of undergoing surgery. Over two thirds of those not undergoing surgery had a co-morbidity score of 1 or more compared with 44.0% of surgical patients. Those not receiving surgery were also more likely to need help with ADL ($P<0.001$) with 63.4% of these non-surgical patients having a ECOG performance status score of 2 or more compared with 26.4% of women having surgery ($P<0.001$). Non-surgical patients also had a slightly lower body mass index ($P=0.006$) and were more likely to smoke ($P=0.007$).

Multivariable analysis. A logistic regression analysis was carried out to investigate whether age is a predictor of primary surgery for operable breast cancer. There was no significant difference between the observed and values predicted by the final model (goodness of fit test χ^2 (Hosmer–Lemeshow) = 5.88: d.f. = 8; $P=0.661$) and model discrimination (AUC = 0.871) considered excellent (Hosmer and Lemeshow, 2000). The results of the univariable and main multivariable regression model are shown in Table 6.

In univariable analysis, the odds of receiving surgery diminished substantially with increasing age, for all age groups with women aged 75–79 years having 0.40 (95% CI: 0.22–0.73) the odds of surgery compared with women aged 70–74 years. After controlling for the effect of patient choice, health and tumour characteristics only the oldest age group had significantly reduced odds of surgery with women aged ≥85 years having just over one fifth of the odds of receiving surgery compared with 70–74-year-olds (OR 0.21, 95% CI: 0.10–4.46). Women perceiving themselves as passive in the decision of whether or not to have surgery had the same chance of having surgery as women adopting an active role. However, those reporting that the choice between surgery and no surgery was not discussed with them had over three and a half times the odds of having surgery compared with women who said this option was discussed (OR 3.54, 95% CI: 1.97–6.37). Although co-morbidity had a significant effect in the univariable analyses, once other health measures were adjusted for, the effect of co-morbidity lost significance. Conversely, EORTC quality of life measure, ELPHS ADL functional status measure and smoking status produced significant effects in the main model with poorer health predicting lack of surgery. For example, for each point increase on the 1–4 ADL scale, indicating poorer functional status/decreasing independence, the odds of surgery reduce by over a third (OR 0.36, 95% CI: 0.24–0.55). Also non-smokers have over two and a half times the odds of undergoing surgery compared with smokers (OR 2.60, 95% CI: 1.18–5.73). The tumour characteristics of oestrogen/ progesterone steroid receptor positivity and tumour size showed a significant effect in the univariable analyses, but this did not remain once the other explanatory variables were adjusted for.

Surgeon's perception of patient role in the decision of whether or not to have surgery was significant in the univariable analyses

Table 5. Health measures by age and surgery

Measure	Age (years)	Scores	P*	Surgery	Scores	P*
ELPHS ADL self report 1–4 inc = worse	70–74	1.44 (1.37–1.51)		Yes	1.57 (1.52–1.62)	
	75–79	1.72 (1.63–1.81)		No	2.42 (2.30–2.55)	<0.001[a]
	80–84	1.77 (1.66–1.87)				
	85 +	2.20 (2.07–2.32)	<0.001[b]			
SF12 PCS self report 1–100 inc = better	70–74	46.83 (45.38–48.28)		Yes	45.02 (44.10–45.95)	
	75–79	42.59 (40.84–44.33)		No	32.43 (30.15–34.70)	<0.001[a]
	80–84	41.47 (39.53–43.40)				
	85 +	37.88 (35.63–40.13)	<0.001[b]			
EORTC QLQ self report 1–100 inc = better	70–74	72.59 (70.12–75.05)		Yes	69.83 (68.13–71.52)	
	75–79	63.93 (60.41–67.44)		No	48.23 (43.67–52.79)	<0.001[a]
	80–84	63.41 (59.74–67.09)				
	85 +	61.89 (57.75–66.04)	<0.001[b]			
PS self report 0–4 categories, inc = worse, % > 1	70–74	20.97 (16.06–25.89)		Yes	26.36 (22.95–29.77)	
	75–79	31.90 (25.85–37.94)		No	63.36 (55.00–71.72)	<0.001[c]
	80–84	36.99 (29.06–44.91)				
	85 +	52.67 (44.01–61.34)	<0.001[d]			
6CIT (0–28) inc = worse, % > 7 i.e., mild/mod cog impair	70–74	10.89 (7.06–14.73)		Yes	12.79 (10.10–15.49)	
	75–79	12.02 (7.56–16.48)		No	25.00 (16.54–33.46)	0.002[c]
	80–84	13.85 (7.83–19.86)				
	85 +	30.10 (21.09–39.11)	<0.001[d]			
Body mass index	70–74	28.46 (27.76–29.17)		Yes	27.90 (27.48–28.31)	
	75–79	28.25 (27.49–29.00)		No	26.60 (25.50–27.69)	0.006[a]
	80–84	27.29 (26.56–28.02)				
	85 +	25.54 (24.70–26.38)	<0.001[b]			
Smoking status (% non-smokers)	70–74	87.96 (84.08–91.83)		Yes	92.15 (90.09–94.20)	
	75–79	88.94 (84.90–92.98)		No	84.09 (77.77–90.41)	0.007[c]
	80–84	96.67 (93.76–99.57)				
	85 +	93.33 (89.07–97.60)	0.008[d]			
Charlson co-morbidity, % ≥ 1	70–74	41.09 (35.24–46.94)		Yes	43.98 (40.19–47.76)	
	75–79	51.27 (44.85–57.69)		No	67.65 (59.68–75.61)	<0.001[c]
	80–84	50.99 (42.93–59.06)				
	85 +	52.90 (44.47–61.33)	0.016[d]			

Abbreviations: 6CIT = 6-Item Cognitive Impairment Test (scale 0–28: increase indicates worse cognitive impairment, 0–7 indicates normal); ECOG-PS = Eastern Co-operative Oncology Group – Performance Status (0–5 categories indicate decreasing functional status); ELPHS ADL = Elderly Population Health Status Survey's Activity of Daily Living (scale 1–4: increase indicates worse functional status); EORTC QLQ-C30 = European Organization for Research on Treatment of Cancer Quality of Life Questionnaire (version 3) Global Quality of Life scale 1–100 (increase indicates better health related quality of life); SF-12 = Short Form-12 Physical Component Summary (scale 1–100: increase indicates better health status). Values for scores are mean (95% confidence interval) unless indicated otherwise.
[a]Mann–Whitney.
[b]Kruskal–Wallis χ^2.
[c]Fisher's exact.
[d]χ^2 for trend.
*All P-values are <0.05.

(Table 7). Similar to the patients' perception measure, if surgeons perceived that the option of surgery (*vs* no surgery) was not discussed, the patient had over five and a half times the odds of having surgery (OR 5.59, 95% CI: 2.49–12.55). However, after adjusting for the other explanatory variables, this effect failed to retain significance. Owing to the smaller sample size available to this subgroup analyses, all non-significant variables were dropped and, of the health measures, only ELPHS ADL was retained as this produced the strongest effect in the main model. The addition of surgeons' perceptions in this nested model does not alter much the effect of age on chance of surgery. After adjusting for patient choice, as well as functional health status, women aged ≥ 85 years still have around a fifth of the odds of surgery compared with 70–74-year-olds (OR 0.18, 95% CI: 0.07–0.44).

DISCUSSION

In this prospective cohort study of 800 women aged ≥ 70 years diagnosed with invasive operable breast cancer, women aged ≥ 85

years were less likely to have surgery adjusting for the effects of patient health and choice. The reduction in surgical rates with increasing age demonstrated in this study is in broad agreement with previous studies both in the UK (Golledge *et al*, 2000; Wyld *et al*, 2004; Lavelle *et al*, 2007a,b, 2012) and elsewhere (Hillner *et al*, 1996; Giordano *et al*, 2005; Naeim *et al*, 2006). However, previous studies reporting unadjusted surgical rates demonstrate reduced odds of surgery from the age of 70 years and older (Bastiaannet *et al*, 2010; Lawrence *et al*, 2011; Tang *et al*, 2011); a pattern also demonstrated in our unadjusted odds reported here. Once patient health and choice were adjusted for, both the location and size of effect changed. Although the pattern of decreased odds of surgery with increasing age remained, only the oldest women aged ≥ 85 years retained significantly reduced odds of surgery; around a fifth for adjusted odds compared with those aged 70–74-year-olds *vs* a tenth for unadjusted odds. However, neither patient health nor choice accounts for the lack of surgery for the oldest women aged ≥ 85 years.

This reduction in effect size, to the point of non-significance, for 75–84-year-olds appears to be largely driven by adjustment for measures of health rather than patient choice. In the main and

Table 6. Multivariable (main) logistic regression of receiving primary surgery (vs not receiving primary surgery) (n = 674)						
Variable[a]	Unadjusted odds ratio	95% CI	P-value*	Adjusted odds ratio[b]	95% CI	P-value*
Age group						
70–74	(ref)	—	—	(ref)	—	—
75–79	0.40	0.22–0.73	**0.003**	0.69	0.32–1.50	0.354
80–84	0.37	0.19–0.71	**0.003**	0.54	0.24–1.20	0.131
85 +	0.09	0.05–0.17	**<0.001**	0.21	0.10–0.46	**<0.001**
Patient's views on role CPS						
Active/collab	(ref)	—	—	(ref)	—	—
Passive	0.90	0.53–1.50	0.677	0.89	0.44–1.81	0.750
Not discussed	5.61	3.58–8.81	**<0.001**	3.54	1.97–6.37	**<0.001**
Co-morbidity						
0	(ref)	—	—	(ref)	—	—
1 +	0.38	0.25–0.55	**<0.001**	0.61	0.36–1.05	0.075
EORTC QLQ 1–100 scale inc = better	1.04	1.03–1.05	<0.001	1.02	1.01–1.03	0.005
ELPHS ADL 1–4 scale inc = worse	0.20	0.15–0.27	**<0.001**	0.36	0.24–0.55	**<0.001**
Smoking						
Smoker	(ref)	—	—	(ref)	—	—
Non-smoker	2.22	1.29–3.83	**0.004**	2.60	1.18–5.73	**0.018**
ER or PR						
Positive	(ref)	—	—	(ref)	—	—
Negative	3.95	1.42–11.03	**0.009**	2.82	0.86–9.25	0.086
Tumour size (mm)	0.98	0.97–1.00	**0.013**	1.00	0.98–1.02	0.695

Abbreviations: CI = confidence interval; CPS = Control Preferences Scale; ELPHS ADL = Elderly Population Health Status Survey's Activity of Daily Living; EORTC QLQ = European Organization for Research on Treatment of Cancer Quality of Life Questionnaire; ER = oestrogen receptor; PR = progesterone receptor.
[a]Health measures 6CIT, BMI and ECOG performance status were not included as there was no significant effect in the initial multivariable model. SF12 PCS was removed as it produced VIFs > 10. Tumour stage, nodal status, socio-economic classification and type of hospital treated at were removed as they did not significantly improve the fit of the model.
[b]Adjusted for all other variables in the table. All variance inflation factors < 10. Goodness of fit test χ^2 Hosmer–Lemeshow = 5.88: d.f. = 8; P = 0.661. Area under receiver operator characteristics curve = 0.871. *P-values < 0.05 are shown in bold.

nested models only whether or not the patient perceived the surgical treatment decision was discussed remained significant. Measuring and adjusting for patient choice in terms of responsibility for treatment decisions builds on previous research, which either simply records whether a treatment option was offered or whether 'patient choice' is listed as a reason for lack of treatment in case notes. As Hamaker et al (2013), point out this latter approach is flawed because 'what is stated to be the patient's preference could in fact be a reflection of the physician's preference' (p550). In our prospective cohort we measure responsibility for the surgical treatment decision from both the surgeon's and the patient's perspective using the previously validated CPS (Degner et al, 1997). On the basis of responses to the CPS there is no evidence that there was active choice not to have surgery among those who did not have surgery. These findings suggest that the lack of surgery for the oldest patients is not due to them actively opting out of having this treatment. However, actually having the discussion about not having/having surgery is associated with reduced likelihood of receiving surgery. Tang et al (2011) also found that 58.9% (66 out of 112) breast cancer patients aged >70 years did not go on to have surgery after being offered a choice of this or treatment with hormone therapy. A likely explanation for this is that the option of not having surgery is only offered/discussed if there are concerns about the patient undergoing surgery.

Among the measures of heath, the strongest predictor of undergoing surgery was the functional status measure of ADL. Activities of Daily Living has been shown in previous studies to predict access to and outcomes from surgery in terms of complications and HRQoL (Extermann and Hurria, 2007; Lavelle et al, 2007a; Audisio et al, 2008; Pal et al, 2010). ADL measures the ability to function independently in everyday life and is a consistent component of the Comprehensive Geriatric Assessment; a battery of varying health status and functional tests recommended by the International Society for Geriatric Oncology as an essential element of treatment decision making for older cancer patients (Biganzoli et al, 2012). The European Organisation for Research and Treatment of Cancer also states that 'maintenance of function and independence should be one of the major principles of cancer management in the elderly' (Pallis et al, 2010). The strength of ADL's prediction of having surgery, both in this and previous studies, suggest that maintenance of independence is a pivotal consideration for older patients contemplating surgery.

The ECOG PS scale also measures functional status and has been shown to predict surgical outcomes for older cancer patients (Audisio et al, 2008). With the added attraction of brevity (5 items vs 18 in the ELPHS ADL), it is collected by some NHS breast care teams as part of the Cancer Outcomes and Services Dataset (NCIN, National Cancer Intelligence Network, 2013). However, although ECOG PS was associated with surgery in the univariable analyses, its effect lost significance once ELPHS ADL along with other measures of health were adjusted for. Previous studies suggest that ECOG PS may lack sensitivity as although 70–80% of older adults with cancer present with an ECOG PS of 0–1 (indicating at least capable of all basic self-care), greater than half require assistance

Table 7. Multivariable (nested) logistic regression of receiving primary surgery (*vs* not receiving primary surgery) adjusting for surgeons' views on role of patient in surgical decision (n = 473)

Variable[a]	Unadjusted odds ratio	95% CI	*P*-value*	Adjusted odds ratio[b]	95% CI	*P*-value*
Age group						
70–74	(ref)	—	—	(ref)	—	—
75–79	0.40	0.22–0.73	**0.003**	0.60	0.25–1.48	0.267
80–84	0.37	0.19–0.71	**0.003**	0.48	0.19–1.21	0.118
85 +	0.09	0.05–0.17	**<0.001**	0.18	0.07–0.44	**<0.001**
Patient's view of role CPS						
Active/collab	(ref)			(ref)	—	—
Passive	0.90	0.53–1.50	0.677	0.70	0.30–1.62	0.404
Not discussed	5.61	3.58–8.81	**<0.001**	2.69	1.34–5.39	**0.005**
Surgeon's view of role CPS						
Active/collab	(ref)	—	—	(ref)	—	—
Passive	1.31	0.55–2.32	0.736	0.64	0.24–1.66	0.355
Not discussed	5.59	2.49–12.55	**<0.001**	2.37	0.93–6.04	0.072
ELPHS ADL 1–4 scale inc = worse	0.20	0.15–0.27	**<0.001**	0.23	0.15–0.35	**<0.001**

Abbreviations: CI = confidence interval; CPS = Control Preferences Scale.
[a]Co-morbidity, ER/PR and tumour size were not included as there was no significant effect in the main multivariable model. ELPHS ADL was retained as it showed the strongest effect among the health measures with significant effect in the main model. EORTC QLQ and smoking status were therefore not included.
[b]Adjusted for all other variables in the table. All variance inflation factors <10. Goodness of fit test χ^2 Hosmer–Lemeshow = 10.90: d.f. = 8; $P = 0.208$. Area under receiver operator characteristic curve = 0.869. *P-values <0.05 are shown in bold.

with the more advanced/instrumental ADLs such as housework, meal preparation and shopping (Extermann, 2000; Pal *et al*, 2010). ADL therefore is more likely to have sufficient sensitivity to identify patients on the threshold of needing additional help to maintain independence. At the point of making the decision to have surgery or not, this may enable post-surgical-care packages to be put in place pre-operatively if necessary.

Although co-morbidity was associated with surgery in univariable analyses, its effect lost significance in the main multivariable model adjusting for other measures of health. Co-morbidity has been found to predict lack of treatment in several previous studies of older women with breast cancer (Ballard-Barbash *et al*, 1996; Hérbert-Croteau *et al*, 1999; Giordano *et al*, 2005; Naeim *et al*, 2006; Lavelle *et al*, 2012). However, this is by no means a universal finding (Hillner *et al*, 1996; Silliman *et al*, 1997; Mandelblatt *et al*, 2000; Lavelle *et al*, 2007a), particularly in studies, which also adjusted for measures of functional/health status (Silliman *et al*, 1997; Mandelblatt *et al*, 2000; Lavelle *et al*, 2007a). This suggests that measures of functional/health status may have a stronger bearing on treatment decision making than co-morbidity for older breast cancer patients. This may particularly be the case for long standing chronic co-morbidities, such as diabetes or asthma, which may be well managed and therefore have little impact on everyday function or indeed the decision to have surgery for breast cancer or not.

There is some evidence that surgical rates are improving for older women with breast cancer in the UK. The overall surgical rate in the study reported here (83.0% in 2010–2013) would fall in line with the increase over time reported in our previous study based on cancer registry data, from 67.4% in 1997–1999 to 75.1% in 2003–2005 (Lavelle *et al*, 2012). Although this may, in part, reflect improving completeness of treatment data, increasing surgical rates over time have also been reported in national audits (NCASP, National Clinical Audit Support Programme, 2009). It therefore seems likely that the improved surgical rates also demonstrate changes in practice, reflecting the guidelines that were published and the major reorganising of cancer services over the

last 15 years (DH, Department of Health, 2000, 2007; ABS at BASO, Association of Breast Surgeons at British Association of Surgical Oncologists, 2009; NICE, National Institute for Clinical Excellence, 2009; DH, Department of Health, 2011).

Compared with all breast cancers registered in England in 2011 our sample under represented women aged ⩾85 years, that is, 26.0% nationally (ONS, Office of National Statistics, 2011) compared with 17.3% (95% CI: 14.7–20.0%) in the study reported here. This may be due to the exclusion of advanced/inoperable breast cancer in our sample as older patients are more likely to present at a later stage at which the tumour is advanced/inoperable (Ramirez *et al*, 1999). However, the under-representation of older patients is also likely to be due in part to selection bias, as participants needed to be capable of consent and be interviewed in order to take part in the study. Nevertheless, the proportion of patients having a Charleson co-morbidity score of ⩾1 (48.0%, 95% CI: 44.5–51.5%) is similar to that found in previous studies, which measure breast cancer patients co-morbidity prospectively (Ring *et al*, 2011; Lavelle *et al*, 2012). For example, Ring *et al* found 44.5% (95% CI: 41.6–47.5%) of patients aged ⩾70 years taking part in the ATAC trial had a Charleson score of ⩾1. Similarly, our estimates of ADL are in line with our own (Lavelle *et al*, 2007a) and others (Sharples *et al*, 2000) estimates in studies of older adults living in the community. However, these previous studies are likely to be subject to the same influence of selection bias and it is probable that older women unable to consent/take part in an interview would have poorer health than younger ones who can. Selection bias towards younger and probably physically healthier women may have limited the generalisability of the study. Yet the results still clearly demonstrated a reduction in standard surgery for women aged ⩾85 years. A larger sample including older less healthy women would have been expected to increase the association between increasing age and non-standard management of breast cancer.

In this study the lack of surgery for 75–84-year-olds could be explained by differences in health status. However, once health measures as well as patient role in treatment decision were adjusted

for, women aged ⩾85 years were still less likely to have surgery. Although surgical rates for older breast cancer patients appear to be increasing, lack of surgery for women aged ⩾85 years persists even when health and patient choice are adjusted for. These findings suggest that, as defined by national policy, 'inappropriate undertreatment' is still occurring for this oldest age group in the UK.

REFERENCES

ABS at BASO, Association of Breast Surgeons at British Association of Surgical Oncologists (2009) Surgical guidelines for the management of breast cancer. *Eur J Surg Oncol* **35**(Suppl 1): 1–22.

APPGBC, All Party Parliamentary Group on Breast Cancer (2013) Age is just a number: The report of the parliamentary inquiry into older age and breast cancer. Westminster, London.

Audisio RA, Pope D, Ramesh HS, Gennari R, van Leeuwen BL, West C, Corsini G, Maffezzini M, Hoekstra HJ, Mobarak D, Bozzetti F, Colledan M, Wildiers H, Stotter A, Capewell A, Marshall E (2008) Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. *Crit Rev Oncol Hematol* **65**: 156–163.

Audisio RA, Ramesh H, Longo WE, Zbar AP, Pope D (2005) Preoperative assessment of surgical risk in oncogeriatric patients. *Oncologist* **10**: 262–268.

Ballard-Barbash R, Potsky AL, Harlan LC, Nayfield SG, Kessler LG (1996) Factors associated with surgical and radiation therapy for early stage breast cancer in older women. *J Natl Cancer Inst* **88**: 716–726.

Bastiaannet E, Liefers GJ, de Craen AJ, Kuppen PJ, van de WW, Portielje JE, van der Geest LG, Janssen-Heijnen ML, Dekkers OM, van d V, Westendorp RG (2010) Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. *Breast Cancer Res Treat* **124**: 801–807.

Bertin ML, Crowe J, Gordon SM (1998) Determinants of surgical site infection after breast surgery. *Am J Infect Control* **26**(1): 61–65.

Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, Reed M, Ciatto S, Voogd AC, Brain E, Cutuli B, Terret C, Gosney M, Aapro M, Audisio R (2012) Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). *Lancet Oncol* **13**: e148–e160.

Bland M (2005) *An Introduction to Medical Statistics*. Oxford University Press: Oxford.

Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G (2007) Older female cancer patients: importance, causes, and consequences of undertreatment. *J Clin Oncol* **25**: 1858–1869.

Brooke P, Bullock R (1999) Validation of a 6 item cognitive impairment test with a view to primary care usage. *Int J Geriatr Psychiatry* **14**: 936–940.

Cancer Research UK (2012) Breast Cancer Survival Statistics. http://info. cancerresearchuk.org/cancerstats/types/breast/survival/#age24-9-2013.

Charlson M, Pompei P, Ales K, MacKenzie C (1987) A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. *J Chronic Dis* **40**: 373–383.

Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA, Module ICBP (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. *Lancet* **377**(9760): 127–138.

Coleman MP, Quaresma M, Berrino F, Lutz JM, De AR, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, Micheli A, Sant M, Weir HK, Elwood JM, Tsukuma H, Koifman S, GA ES, Francisci S, Santaquilani M, Verdecchia A, Storm HH, Young JL. CONCORD Working Group (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol* **9**(8): 730–756.

Degner LF, Kristjanson LJ, Bowman D, Sloan JA, Carriere KC, O'Neil J, Bilodeau B, Watson P, Mueller B (1997) Information needs and decisional preferences in women with breast cancer. *JAMA* **277**(18): 1485–1492.

DH, Department of Health (2000) *The NHS Cancer Plan: a plan for investment, a plan for reform*. NHS: London.

DH, Department of Health (2007) *Cancer Reform Strategy*. NHS: London.

DH, Department of Health (2011) *Improving Outcomes: A Strategy for Cancer*. London.

Extermann M (2000) Measuring comorbidity in older cancer patients. *Eur J Cancer* **36**: 453–471.

Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. *J Clin Oncol* **25**: 1824–1831: London, UK.

Extermann M, Overcash J, Lyman G, Parr J, Balducci L (1998) Co-morbidity and functional status are independent in older cancer patients. *J Clin Oncol* **16**: 1582–1587.

Foot C, Harrison T (2011) *How to Improve Cancer Survival: Explaining England's Relatively Poor Rates*. The King's Fund.

Giordano SH, Hortobagyi GN, Kau S-WC, Theriault RL, Bondy ML (2005) Breast cancer treatment guidelines in older women. *J Clin Oncol* **23**: 783–791.

Golledge J, Wiggins JE, Callam MJ (2000) Age-related variation in the treatment and outcomes of patients with breast carcinoma. *Cancer* **88**: 369–374.

Hamaker ME, Bastiaannet E, Evers D, Van de Water W, Smorenburg CH, Maartense E, Zeilemaker AM, Liefers GJ, van der Geest L, de Rooij SE, van Munster BC, Portielje JEA (2013) Omission of surgery in elderly patients with early stage breast cancer. *Eur J Cancer* **49**: 545–552.

Haywood K, Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R (2004) *Health status and quality of life in older People: a structured review of patient-assessed health instruments reported from the Patient-assessed Health Instruments Group to the Department of Health*. Department of Health: London.

Hérbert-Croteau N, Brisson J, Latreille J, Blanchette C, Deschênes L (1999) Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. *Cancer* **85**: 1104–1113.

Hillner BE, Penberthy L, Desch CE, McDonald MK, Smith TJ, Retchin SM (1996) Variation in staging and treatment of local and regional breast cancer in the elderly. *Breast Cancer Res Treat* **40**: 75–86.

Hind D, Wyld L, Reed MW (2007) Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review. *Br J Cancer* **96**: 1025–1029.

Hosmer DW, Lemeshow S (2000) *Applied Logistic Regression*. John Wiley: New York.

Janz NK, Wren PA, Copeland LA, Lowery JC, Goldfarb SL, Wilkins EG (2004) Patient-physician concordance: preferences, perceptions, and factors influencing the breast cancer surgical decision. *J Clin Oncol* **22**: 3091–3098.

Kutner M, Nachtsheim C, Neter J (2004) *Applied Linear Regression Models*, 4th edn. McGraw-Hill Irwin: New York.

Landis J, Koch G (1977) The measurement of observer agreement for categorical data. *Biometrics* **33**: 159–174.

Lavelle K, Downing A, Thomas JD, Lawrence G, Forman D, Oliver SE (2012) Are lover rates of surgery amongst older women with breast cancer in the UK explained by co-morbidity? *Br J Cancer* **107**: 1175–1180.

Lavelle K, Moran A, Howell A, Bundred N, Campbell M, Todd C (2007a) Older women with operable breast cancer are less likely to have surgery. *Br J Surg* **94**: 1209–1215.

Lavelle K, Todd C, Moran A, Howell A, Bundred N, Campbell M (2007b) Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or = 65 years. *Br J Cancer* **96**: 1197–1203.

Lawrence G, Kearins O, Lagord C, Cheung S, Sidhu J, Sagar C (2011) *The Second All Breast Cancer Report*. National Cancer Intelligence Network: London, UK.

Louwman WJ, Vulto JC, Verhoeven RH, Nieuwenhuijzen GA, Coebergh JW, Voogd AC (2007) Clinical epidemiology of breast cancer in the elderly. [Review] [44 refs]. *Eur J Cancer* **43**: 2242–2252.

MacMillan Cancer Support, Age UK and the Department of Health (2012) *Cancer Services Coming of Age: Learning from the Improving Cancer Treatment Assessment and Support for Older People Project*. MacMillan Cancer Support: London.

Mandelblatt JS, Hadley J, Kerner JF, Schulman KA, Gold K, Dunmore-Griffith J, Edge S, Guadagnoli E, Lynch JJ, Meropol NJ, Weeks JC, Winn R (2000) Patterns of breast carcinoma treatment in older women: patient preference and clinical and physician influences. *Cancer* **89**: 561–573.

Moller H, Flatt G, Moran A (2011) High cancer mortality rates in the elderly in the UK. *Cancer Epidemiol* **35**: 407–412.

Naeim A, Hurria A, Leake B, Maly RC (2006) Do age and ethnicity predict breast cancer treatment received? A cross-sectional urban population based study. Breast cancer treatment: age and ethnicity. *Crit Rev Oncol Hematol* **59**: 234–242.

NCASP, National Clinical Audit Support Programme (2009) National mastectomy and breast reconstruction audit. http://www.hscic.gov.uk/searchcatalogue?productid=59&q=NCASP%2c + National + Clinical + Audit + Support + Programme. + National + mastectomy + and + breast + reconstruction + audit. + &sort=Relevance&size=10&page=1#top (accessed 24 September 2013).

NCIN, National Cancer Intelligence Network (2013) Cancer Outcomes and Services Dataset, http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd.

NICE, National Institute for Clinical Excellence (2009) Early and locally advanced breast cancer: diagnosis and treatment. NICE: London.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* **5**: 649–655.

ONS, Office of National Statistics (2010) Ethnic group (2001 Census), http://data.gov.uk/dataset/ethnic_group_2001_census24-9-2013.

ONS, Office of National Statistics (2011) Cancer statistics registrations: Registrations of cancer diagnosed in 2009, England. Series MB1 No. 40. www.statistics.gov.uk.

ONS, Office of National Statistics (2013) The National Statistics Socio-Economic Classification (NS-SEC rebased on the SOC2010), http://www.ons.gov.uk/ons/guide-method/classifications/current-standard-classifications/soc2010/soc2010-volume-3-ns-sec–rebased-on-soc2010–user-manual/index.html.

Osoba D, Aaronson N, Sprangers M, te Velde A (1997) Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. *Qual Life Res* **6**: 103–108.

Pal SK, Katheria V, Hurria A (2010) Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. *CA Cancer J Clin* **60**: 120–132.

Pallis AG, Fortpied C, Wedding U, Van Nes MC, Penninckx B, Ring A, Lacombe D, Monfardini S, Scalliet P, Wildiers H (2010) EORTC elderly task force position paper: approach to the older cancer patient. *Eur J Cancer* **46**: 1502–1513.

Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR (1996) A simulation study of the number of events per variable in logistic regression analysis. *J Clin Epidemiol* **49**(12): 1373–1379.

Ramirez A, Westcombe A, Burgess C, Sutton S, Littlejohns P, Richards MA (1999) Factors predicting delay in the presentation and treatment of symptomatic breast cancer: a systematic review. *Lancet* **353**: 1127–1131.

Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J (2011) Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen alone or in combination trial. *J Clin Oncol* **29**: 4266–4272.

Sharples LD, Todd CJ, Caine N, Tait S (2000) Measurement properties of the Nottingham Health Profile and Short Form 36 health status measures in a population sample of elderly people living at home: results from ELPHS. *Br J Health Psychol* **5**: 217–233.

SIGN, Scottish Intercollegiate Guidelines Network (1998) *Breast Cancer in Women: A National Clinical Guideline Recommended for Use in Scotland*. Royal College of Physicians: Edinburgh.

SIGN, Scottish Intercollegiate Guidelines Network (2005) *Management of Breast Cancer in Women: A National Clinical Guideline*. Royal College of Physicians: Edinburgh.

Silliman RA, Troyan S, Guadagnoli E, Kaplan S, Greenfield S (1997) The impact of age, marital status and physician-patient interaction on the care of older women with breast carcinoma. *Cancer* **80**: 1326–1334.

Sorensen LT, Horby J, Friis E, Pilsgaard B, Jorgensen T (2002) Smoking as a risk factor for wound healing and infection in breast cancer surgery. *Eur J Surg Oncol* **28**: 815–820.

Sturgis P, Thomas R, Purdon S, Bridgwood A, Dodd T (2001) *Comparative Review and Assessment of Key Health State Measures of the General Population*. Department of Health: London.

Tang SW, Parker H, Winterbottom L, Hassell K, Ellis IO, Morgan DA, Cheung KL (2011) Early primary breast cancer in the elderly - pattern of presentation and treatment [Review]. *Surg Oncol* **20**: 7–12.

UICC (2009) *TNM Classification of Malignant Tumours*, 7th edn. Wiley-Blackwell: Oxford.

Ware J, Konsinski M, Turner-Bowker D, Gandek B (2002) *How to Score Version 2 of the SF-12(R) Health Survey (with a Supplement Documenting Version 1)*. QualityMetric Incorporated: Lincoln, RI.

WHO (1948) Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, 19–22 June 1946; signed on 22 July 1946 by the representatives of 61 States (Official Records of the World Health Organization, no. 2, p. 100) and entered into force on 7 April 1948. World Health Organisation: Geneva.

Wyld L, Garg D, Kumar I, Brown H, Reed M (2004) Stage and treatment variation with age in postmenopausal women with breast caner: compliance with guidelines. *Br J Cancer* **90**: 1486–1491.